News for Agent

Daily business news: funding, M&A, launches

Regulation & Approvals

DNV Certifies FAMID Biomedical's Class C Cervical Cancer Test Under IVDR in Six Months

By ·

Key takeaways

  • DNV issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic.
  • The certification was completed in six months after assessment of quality management, clinical evidence and technical documentation.
  • The test is intended for both professional laboratory use and self-testing and supports European market access.

DNV has issued an IVDR certificate to FAMID Biomedical Technology (Tianjin) Co., Ltd for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic designed to aid the diagnosis of cervical precancerous lesions. The certification was completed in six months, Newswire reported on November 19, 2026.

How the FAMID Assessment Worked

DNV is an EU Notified Body for the In Vitro Diagnostic Medical Devices Regulation. The certification followed assessment of FAMID Biomedical's quality management system, clinical evidence and technical documentation.

The E7 Oncoprotein Rapid Test Kit detects HPV E7 oncoprotein in cervical cell samples. The product is intended for both professional laboratory use and self-testing.

Jim Miao, CEO of FAMID Biomedical Technology, said: "Bringing medical technologies to market requires not only strong technical capabilities, but also a certification partner who understands the importance of timely market access."

Cecilie Gudesen Torp, Managing Director of Medical Technologies, Life Sciences at DNV, said: "Achieving IVDR certification just six months after contract signing is a significant achievement and reflects both FAMID Biomedical Technology's preparation and the expertise and close coordination of our teams throughout the assessment process."

DNV's Medical Technology Business

DNV is a Norway-founded assurance and risk management company founded in 1864, providing classification, certification, verification, inspection, testing and advisory services to maritime, energy, healthcare and industrial clients, according to akta.pro company records. The company is headquartered in Høvik and has an estimated revenue of $1 billion-$5 billion.

DNV's medical technology work sits alongside its maritime operations, which span roughly 180 offices worldwide and more than 65 countries, the same records show. DNV has built specialist IVDR competence and capacity across its global Medical Technologies organisation and is working with a growing portfolio of IVD manufacturers globally.

Earlier DNV Diagnostic Findings

On November 18, 2026, PR Newswire reported that a DNV survey of 12,500 people across 17 countries found 67% of respondents rated home diagnostic tests as very helpful, compared with 33% who rated them as very accurate. A similar gap appeared for home medical devices, with 68% helpful and 36% accurate.

On October 29, 2026, Offshore News reported that DNV issued a Statement of Feasibility for Aker BP and Höegh Evi's concept to transport liquefied CO2 by shuttle carriers and inject it directly into subsea wells at the Atlas project offshore Norway.

What Comes Next for FAMID

FAMID Biomedical said the certification supports its expansion into new markets, and DNV said the certificate supports bringing the diagnostic technology to the European market.

Companies in this story

Sources

Machine-readable: Markdown · JSON